Targeting pancreatic cancer using a combination of gemcitabine with the omega‐3 polyunsaturated fatty acid emulsion, Lipidem™

Authors:

Abstract
Scope: Pancreatic cancer remains a disease of poor prognosis, with alternate strategies being sought to improve therapeutic efficacy. Omega‐3 fatty acids have shown clinical benefit, and mechanisms of action are under investigation.Methods and results: Proliferation assays, flow cytometry, invasion assays, ELISA and western blotting were used to investigate efficacy of omega‐3 fatty acids alone and in combination with gemcitabine. The docosahexanoic acid (DHA)/eicosapentanoic acid (EPA) combination, Lipidem™, in combination with gemcitabine inhibited growth in pancreatic cancer and pancreatic stellate cell (PSC) lines, with PSCs exhibiting greatest sensitivity to this combination. Invasion of pancreatic cancer cells and PSCs in a 3D spheroid model, was inhibited by combination of gemcitabine with Lipidem™. PSCs were required for cancer cell invasion in an organotypic co‐culture model, with invasive capacity reduced by Lipidem™ alone. Platelet‐derived growth factor (PDGF) is a key cytokine in pro‐proliferative and invasion signalling, and thus a critical regulator of interactions between pancreatic cancer cells and adjacent stroma. Platelet‐derived growth factor (PDGF‐BB) secretion was completely inhibited by the combination of Lipidem™ with gemcitabine in cancer cells and PSCs.Conclusion: Lipidem™ in combination with gemcitabine, has anti‐proliferative and anti‐invasive efficacy in vitro, with pancreatic stellate cells exhibiting the greatest sensitivity to this combination.
Funding Information
  • Department of Health on an Experimental Cancer Medicine Centre (C325/A15575)

This publication has 26 references indexed in Scilit: